grant
Hematologic Malignancies
Organization FRED HUTCHINSON CANCER CENTERLocation SEATTLE, UNITED STATESPosted 1 Jan 1997Deadline 31 Dec 2029
NIHUS FederalResearch GrantFY20250-11 years old21+ years oldAchievementAchievement AttainmentAdultAdult HumanAllogenicAntibody TherapyAntibody-drug conjugatesBiologic ModelsBiologicalBiological ModelsBiologyBiometricsBiometryBiostatisticsBloodBlood Precursor CellBlood Reticuloendothelial SystemBone Marrow GraftingBone Marrow TransplantBone Marrow TransplantationCCSGCancer Center Support GrantCancersCell BodyCell DeathCell-Mediated Lympholytic CellsCellsChildChild YouthChildhood LeukemiaChildren (0-21)ClinicalClinical DataClinical FacultyClinical Nurse EducatorClinical ProtocolsClinical TrialsClinical Trials DesignCollaborationsCongenital PancytopeniaCytolytic T-CellCytotoxic T CellCytotoxic T-LymphocytesCytotoxic cellDNA TherapyDNA mutationDedicationsDefectDevelopmentDiseaseDisorderDrugsDysmyelopoietic SyndromesEngineeringEvolutionFacultyFanconi AnemiaFanconi PanmyelopathyFanconi dysplasiaFanconi's AnemiaFundingGene Transfer ClinicalGenesGenetic ChangeGenetic InterventionGenetic defectGenetic mutationGenomicsGerminoblastic SarcomaGerminoblastomaGoalsGrantHSC transplantationHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematologyHematopoiesisHematopoietic CancerHematopoietic Cell TumorHematopoietic Cellular Control MechanismsHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic Progenitor CellsHematopoietic Stem Cell TransplantHematopoietic Stem Cell TransplantationHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHematopoietic stem cellsImmune mediated therapyImmune systemImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunologyImmunoradiotherapyImmunotherapyInfrastructureInstitutionInterventionK lymphocyteKnowledgeLaboratoriesLifeLong-term Follow-upLymphomaMalignant Hematologic NeoplasmMalignant Hematopoietic NeoplasmMalignant LymphomaMalignant NeoplasmsMalignant TumorMarrow TransplantationMedicationMembrane Protein GeneMembrane ProteinsMembrane-Associated ProteinsModalityModel SystemMolecularMultiple MyelomaMutationMyelodysplastic DiseaseMyelodysplastic SyndromesMyeloid DiseaseMyeloid MalignancyMyeloid NeoplasmMyeloid ProgenitorMyeloid Progenitor CellsMyeloid Stem CellsMyeloid TumorMyeloproliferative DisordersMyeloproliferative TumorsMyeloproliferative diseaseNK CellsNatural Killer CellsNurse EducatorNursing FacultyNursing Staff DeveloperNursing Staff Development SpecialistOncogenesisPaperPathway interactionsPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPediatric LeukemiaPharmaceutical PreparationsPlasma-Cell MyelomaPrimary Erythroid HypoplasiaProgenitor Cell TransplantationProteomicsProviderPublishingQOL improvementRadioimmunotherapyRefractory Anemia with an Excess of BlastsRefractory anaemia with excess blastsResearchReticulolymphosarcomaSafetySamplingScientistSmoldering LeukemiaStem Cell TransplantationStem cell transplantSurface ProteinsSystemT-CellsT-LymphocyteTechnologyTestingTherapeuticToxic effectToxicitiesTranslatingTranslational ResearchTranslational ScienceTransplantationTumor AntigensTumor CellTumor-Associated AntigenViral DiseasesVirus Diseasesadult leukemiaadulthoodanimationantibody based therapiesantibody treatmentantibody-based therapeuticsantibody-based treatmentbiologicblood cancerblood cell formationblood cell progenitorblood progenitorblood stem cellblood stem cell transplantationblood-forming stem cellcancer antigenscancer carecancer of bloodcancer of the bloodchemo-/radio-therapychemo-radiotherapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapychildren with leukemiaclinical implementationcongenital aplastic anemiacurative interventioncurative therapeuticcurative therapycurative treatmentsdata managementdesigndesigningdevelopmentaldriver lesiondriver mutationdrug/agenteffective therapyeffective treatmentfaculty supportgene editing methodgene editing methodologygene editing strategygene editing techniquesgene repair therapygene therapeuticsgene therapygene-based therapeuticgene-based therapeuticsgene-based therapygene-editing approachgenes therapeuticgenes therapeuticsgenetic therapygenome mutationgenomic therapyhematopoietic cell transplantationhematopoietic cellular transplantationhematopoietic progenitorhematopoietic progenitor cell transplantationhematopoietic stem progenitor cellhemopoietic progenitorhemopoietic stem cellimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimprovedimprovements in QOLimprovements in quality of lifeinnovateinnovationinnovativeinsightintervention designkidskiller T cellkinase inhibitorleukemialeukemia in childrenlong-term followupmalignancymembermultidisciplinarymyelodysplasiamyeloid precursormyeloid stem and progenitor cellmyelomamyelomatosismyeloproliferative neoplasmnecrocytosisneoplasm/cancerneoplastic cellnovelpathwaypatient oriented outcomespre-clinicalpreclinicalprogenitor biologyprogenitor cell biologyprogenitor transplantationprogramsquality of life improvementradio-chemo-therapyradio-chemotherapyradiochemotherapyresearch facultyresponseskillssmall moleculestandard of carestem and progenitor biologystem and progenitor cell transplantationsstem cell biologysuccesssynergismtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic genetherapy designthymus derived lymphocytetranslation researchtranslational investigationtransplanttransplant modeltreatment designtumortumor-specific antigentumorigenesisviral infectionvirus infectionvirus-induced diseaseyoungster
Description preview
PROJECT SUMMARY
Blood cancers afflict children and adults and are life-threatening. The Hematologic Malignancies (HM) Program
is dedicated to understanding the causes of blood cancers and developing successful gene, drug, and cellular
treatment options to improve the quality of life and survival of patients. These goals are accomplished through…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click